{"id":7954,"date":"2026-05-06T09:49:05","date_gmt":"2026-05-06T07:49:05","guid":{"rendered":"https:\/\/value-dossier.com\/?p=7954"},"modified":"2026-05-06T09:51:28","modified_gmt":"2026-05-06T07:51:28","slug":"%f0%9d%97%97%f0%9d%97%bf%f0%9d%97%ae%f0%9d%97%b3%f0%9d%98%81-%f0%9d%97%95%f0%9d%97%b6%f0%9d%97%b9%f0%9d%97%b9-%f0%9d%97%95%f0%9d%97%a6%f0%9d%98%81%f0%9d%97%ae%f0%9d%97%af%f0%9d%97%9a-%f0%9d%97%aa","status":"publish","type":"post","link":"https:\/\/value-dossier.com\/en\/%f0%9d%97%97%f0%9d%97%bf%f0%9d%97%ae%f0%9d%97%b3%f0%9d%98%81-%f0%9d%97%95%f0%9d%97%b6%f0%9d%97%b9%f0%9d%97%b9-%f0%9d%97%95%f0%9d%97%a6%f0%9d%98%81%f0%9d%97%ae%f0%9d%97%af%f0%9d%97%9a-%f0%9d%97%aa\/","title":{"rendered":"Draft Bill BStabG: What Matters for Pharmaceutical Companies now"},"content":{"rendered":"\n<section class=\"wrap_outer text-image\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"text\">\n            <div class=\"okd-text\">\n                <p>The current draft bill on statutory health insurance contribution rate stabilization (BStabG) sets out the health policy objective of tighter expenditure control \u2014 with direct implications for pricing, market access, and reimbursement in the German market.<\/p>\n<p>An overview of the key changes for innovative products:<\/p>\n<ul>\n<li><strong>Discontinuation of the AMNOG guardrails and the combination rebate<\/strong><br \/>\nRemoval of complex and controversial legislations.<br \/>\n\u27a1\ufe0f Price negotiations can once again be based more heavily on the extent of the additional benefit<br \/>\n\u27a1\ufe0f The risk of a 20% discount on combination drugs no longer applies.<\/li>\n<li><strong>Dynamic manufacturer discount (\u00a7 130a):<\/strong><br \/>\nRevenue-based budgeting for the pharmaceutical sector.<br \/>\n\u27a1\ufe0f The costs of innovation in the pharmaceutical sector are capped and spread across all patented drugs.<br \/>\n\u27a1\ufe0f The benefit assessment as a pricing tool is becoming less important.<\/li>\n<li><strong>Strengthening of the price-volume model as a central control instrument:<\/strong><br \/>\nGrowth and sales volume are systematically integrated into price development.<br \/>\n\u27a1\ufe0f The arbitration board&#8217;s decision-making practice will be implemented as a legal requirement.<\/li>\n<\/ul>\n<p>The central instrument for cost-control in the pharmaceutical market will be the dynamic manufacturer discount limiting the drug expenditure to the income of the statutory health insurances. The implicit drug budget will have impact on the pricing for new innovative drugs and will create interdependencies between prices for new drugs and patent-protected drugs that are already in the market.<\/p>\n            <\/div>\n        <\/div>\n\n        <div class=\"image\">\n            <img loading=\"lazy\" decoding=\"async\" width=\"1402\" height=\"1122\" src=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/05\/ChatGPT-Image-Apr-23-2026-11_35_58-AM.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/05\/ChatGPT-Image-Apr-23-2026-11_35_58-AM.png 1402w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/05\/ChatGPT-Image-Apr-23-2026-11_35_58-AM-300x240.png 300w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/05\/ChatGPT-Image-Apr-23-2026-11_35_58-AM-1024x819.png 1024w, https:\/\/value-dossier.com\/wp-content\/uploads\/2026\/05\/ChatGPT-Image-Apr-23-2026-11_35_58-AM-768x615.png 768w\" sizes=\"auto, (max-width: 1402px) 100vw, 1402px\" \/>        <\/div>\n\n    <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7954","post","type-post","status-publish","format-standard","hentry","category-nicht-kategorisiert"],"acf":[],"_links":{"self":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/7954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/comments?post=7954"}],"version-history":[{"count":2,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/7954\/revisions"}],"predecessor-version":[{"id":7957,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/7954\/revisions\/7957"}],"wp:attachment":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/media?parent=7954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/categories?post=7954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/tags?post=7954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}